The Apex Times
Above the Noise
Business Wire
BusinessAdobe shares are among the day’s big stock movers, in a broader market read on technology and consumer namesThe Apex TimesBusinessYahoo Finance analysis pits NVIDIA and Broadcom against each other in the AI stock debateThe Apex TimesBusinessCrypto-Linked Stocks Jump as Bitcoin Rally Spurs Buyers in Coinbase and Other Equity ProxiesThe Apex TimesBusinessMorgan Stanley downgrades Baidu, citing rising AI costs and weaker ad momentumThe Apex TimesBusinessEthos plans to present at Goldman Sachs Communacopia + Technology ConferenceThe Apex TimesBusinessWalmart’s latest results seen by retail CIO as a litmus test for whether U.S. shoppers are pulling backThe Apex TimesBusinessTarget’s Quarterly Profit Jumps to $1.88 Billion, Fueling Renewed Hope for a TurnaroundThe Apex TimesBusinessMerck leads, Amgen in second, Pfizer trails in 2026’s stock race among large U.S. drugmakersThe Apex TimesBusinessHome Depot expands express delivery promised in 3 hours or less, using thousands of items and store-based hubsThe Apex TimesBusinessBNY Mellon has outpaced Bank of America and Wells Fargo in 2026’s big-bank stock race, according to Yahoo FinanceThe Apex TimesBusinessNvidia-investor debate revives question of whether chip sales and funding are becoming a loopThe Apex TimesBusinessBerkshire Hathaway’s 13F points to new interest in homebuilding, with D.R. Horton among the buysThe Apex TimesBusinessAdobe shares are among the day’s big stock movers, in a broader market read on technology and consumer namesThe Apex TimesBusinessYahoo Finance analysis pits NVIDIA and Broadcom against each other in the AI stock debateThe Apex TimesBusinessCrypto-Linked Stocks Jump as Bitcoin Rally Spurs Buyers in Coinbase and Other Equity ProxiesThe Apex TimesBusinessMorgan Stanley downgrades Baidu, citing rising AI costs and weaker ad momentumThe Apex TimesBusinessEthos plans to present at Goldman Sachs Communacopia + Technology ConferenceThe Apex TimesBusinessWalmart’s latest results seen by retail CIO as a litmus test for whether U.S. shoppers are pulling backThe Apex TimesBusinessTarget’s Quarterly Profit Jumps to $1.88 Billion, Fueling Renewed Hope for a TurnaroundThe Apex TimesBusinessMerck leads, Amgen in second, Pfizer trails in 2026’s stock race among large U.S. drugmakersThe Apex TimesBusinessHome Depot expands express delivery promised in 3 hours or less, using thousands of items and store-based hubsThe Apex TimesBusinessBNY Mellon has outpaced Bank of America and Wells Fargo in 2026’s big-bank stock race, according to Yahoo FinanceThe Apex TimesBusinessNvidia-investor debate revives question of whether chip sales and funding are becoming a loopThe Apex TimesBusinessBerkshire Hathaway’s 13F points to new interest in homebuilding, with D.R. Horton among the buysThe Apex TimesBusinessAdobe shares are among the day’s big stock movers, in a broader market read on technology and consumer namesThe Apex TimesBusinessYahoo Finance analysis pits NVIDIA and Broadcom against each other in the AI stock debateThe Apex TimesBusinessCrypto-Linked Stocks Jump as Bitcoin Rally Spurs Buyers in Coinbase and Other Equity ProxiesThe Apex TimesBusinessMorgan Stanley downgrades Baidu, citing rising AI costs and weaker ad momentumThe Apex TimesBusinessEthos plans to present at Goldman Sachs Communacopia + Technology ConferenceThe Apex TimesBusinessWalmart’s latest results seen by retail CIO as a litmus test for whether U.S. shoppers are pulling backThe Apex TimesBusinessTarget’s Quarterly Profit Jumps to $1.88 Billion, Fueling Renewed Hope for a TurnaroundThe Apex TimesBusinessMerck leads, Amgen in second, Pfizer trails in 2026’s stock race among large U.S. drugmakersThe Apex TimesBusinessHome Depot expands express delivery promised in 3 hours or less, using thousands of items and store-based hubsThe Apex TimesBusinessBNY Mellon has outpaced Bank of America and Wells Fargo in 2026’s big-bank stock race, according to Yahoo FinanceThe Apex TimesBusinessNvidia-investor debate revives question of whether chip sales and funding are becoming a loopThe Apex TimesBusinessBerkshire Hathaway’s 13F points to new interest in homebuilding, with D.R. Horton among the buysThe Apex TimesBusinessAdobe shares are among the day’s big stock movers, in a broader market read on technology and consumer namesThe Apex TimesBusinessYahoo Finance analysis pits NVIDIA and Broadcom against each other in the AI stock debateThe Apex TimesBusinessCrypto-Linked Stocks Jump as Bitcoin Rally Spurs Buyers in Coinbase and Other Equity ProxiesThe Apex TimesBusinessMorgan Stanley downgrades Baidu, citing rising AI costs and weaker ad momentumThe Apex TimesBusinessEthos plans to present at Goldman Sachs Communacopia + Technology ConferenceThe Apex TimesBusinessWalmart’s latest results seen by retail CIO as a litmus test for whether U.S. shoppers are pulling backThe Apex TimesBusinessTarget’s Quarterly Profit Jumps to $1.88 Billion, Fueling Renewed Hope for a TurnaroundThe Apex TimesBusinessMerck leads, Amgen in second, Pfizer trails in 2026’s stock race among large U.S. drugmakersThe Apex TimesBusinessHome Depot expands express delivery promised in 3 hours or less, using thousands of items and store-based hubsThe Apex TimesBusinessBNY Mellon has outpaced Bank of America and Wells Fargo in 2026’s big-bank stock race, according to Yahoo FinanceThe Apex TimesBusinessNvidia-investor debate revives question of whether chip sales and funding are becoming a loopThe Apex TimesBusinessBerkshire Hathaway’s 13F points to new interest in homebuilding, with D.R. Horton among the buysThe Apex Times
Back to front
Moderna-linked oncology momentum highlights Tempus bid for Personalis in a deal valued at $1.5 billion
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 2:58 PM EDT

Moderna-linked oncology momentum highlights Tempus bid for Personalis in a deal valued at $1.5 billion

A July 20, 2026 merger announcement priced Personalis at a major markup through a Tempus AI acquisition structured as a 100% stock transaction, spotlighting the growing cash value of precision-medicine data platforms.

3 min readEditor-approved Apex article

Tempus AI’s plan to buy Personalis in a transaction announced July 20, 2026 is drawing fresh attention to the market value being placed on next-generation oncology data and analysis. The deal, described by a widely syndicated market-news post, is set at $1.5 billion and is structured as a 100% stock transaction with a Tempus option feature, according to that report.

The Personalis acquisition price cited in the post anchors the discussion around how companies are competing for proprietary sequencing, biomarker, and clinical data pipelines. For investors tracking oncology-focused platforms, the headline number indicates that buyers are willing to pay for both technology and the datasets and workflows those systems support.

While the post frames the $1.5 billion figure as a test of Tempus’s judgment, it also indirectly underscores how public markets are reacting to the broader race to translate cancer biology into actionable treatment decisions. Precision medicine companies increasingly argue that the ability to generate and interpret molecular profiles at scale can improve clinical outcomes, strengthen drug development efforts, and help match patients to therapies.

Moderna, whose research pipeline spans immunology and oncology-adjacent approaches, appears in the framing of the story as part of the wider “cancer breakthrough” narrative. However, the cited market-news article does not provide detailed linkage between Moderna’s specific program results and the Tempus- Personalis deal terms beyond the thematic connection to cancer innovation.

The report’s specifics, based on what is visible in the provided description, center on transaction mechanics rather than operational performance. It mentions a definitive merger announcement, a $1.5 billion price tag, and a 100% stock structure that includes an option component. Those features can matter to holders because stock consideration ties the outcome to the acquirer’s future valuation and the option element can alter how consideration is realized across time or conditions.

Beyond those headline points, the market-news post does not outline the implied valuation range, expected closing timing, regulatory strategy, or any integration milestones. It also does not disclose whether Moderna has any direct commercial, licensing, or partnership exposure to Personalis or Tempus in connection with this transaction.

More broadly, sector participants note that the oncology workflow has shifted from single-instrument diagnostics toward end-to-end platforms that combine lab execution, data interpretation, and clinical decision support. In that context, the Personalis acquisition price cited in the report suggests that data-centric oncology companies are still able to command premium interest when buyers believe their platforms can widen market reach or strengthen evidence for clinicians and drug developers.

Investors will likely watch for what the definitive merger filing says next, including the exchange ratio mechanics for the 100% stock transaction and any disclosures around expected synergies, regulatory hurdles, and leadership or operational plans after the deal closes. Until then, the market-news framing provides a valuation snapshot but leaves many details of rationale and timing unaddressed in the information available here.

Why It Matters

  • The cited $1.5 billion figure indicates that investors and acquirers continue to value oncology data and analytics platforms at premium levels.
  • A stock-and-option structure means Personalis shareholders’ outcomes depend on Tempus’s future trading performance and deal terms.
  • For the precision-medicine sector, the deal reinforces the importance of owning or tightly integrating sequencing and interpretation workflows.
  • The absence of disclosed integration and timing details in the cited market-news post highlights how much additional information may be required from filings to assess execution risk.

Sources

Key Facts

  • A definitive merger between Tempus AI and Personalis was announced on July 20, 2026, according to a market-news report.
  • The report cites a deal value of $1.5 billion for the transaction.
  • The transaction is described as a 100% stock deal.
  • The deal is described as including a Tempus option feature, implying consideration elements beyond straightforward stock exchange.
  • The report frames the deal as a favorable outcome for Tempus’s acquisition thesis tied to cancer analytics and data platforms.

Healthcare Related